Treatment for neovascular age related macular degeneration: The state of the art.

Détails

ID Serval
serval:BIB_B12577C45235
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Treatment for neovascular age related macular degeneration: The state of the art.
Périodique
European journal of pharmacology
Auteur⸱e⸱s
Eandi C.M., Alovisi C., De Sanctis U., Grignolo F.M.
ISSN
1879-0712 (Electronic)
ISSN-L
0014-2999
Statut éditorial
Publié
Date de publication
15/09/2016
Peer-reviewed
Oui
Volume
787
Pages
78-83
Langue
anglais
Notes
Publication types: Journal Article ; Review
Publication Status: ppublish
Résumé
With the introduction in the clinical practice of drugs inhibiting vascular endothelial growth factor (VEGF) the visual outcomes of patients with neovascular age related macular degeneration (AMD) dramatically improved. Since 2006 repeated intravitreal injections of anti-VEGF became the standard of care for the treatment of neovascular AMD. This review provides an overview of available data form clinical trials supporting the use of anti-VEGF molecules for the treatment of this condition. Several questions remain open, in particular the regimen of treatment, the frequency of injection, the safety of the different drugs, and the poor response to the treatment in some cases. Therefore, new agents and alternative delivery are currently under evaluation.
Mots-clé
Animals, Blood Vessels/drug effects, Blood Vessels/metabolism, Blood Vessels/physiopathology, Clinical Trials as Topic, Humans, Macular Degeneration/drug therapy, Macular Degeneration/metabolism, Macular Degeneration/physiopathology, Molecular Targeted Therapy/adverse effects, Molecular Targeted Therapy/methods, Safety, Vascular Endothelial Growth Factor A/metabolism, Angiogenesis, Anti-VEGF, Choroid, Degeneration, Macula, Retina
Pubmed
Web of science
Création de la notice
12/03/2021 18:13
Dernière modification de la notice
26/03/2021 6:35
Données d'usage